----------------------- Page 1-----------------------

                                                                                                                                                                                                                       6 

                                                                              ®                                                                               a                                                        7 

      Table 2. 2019 American Geriatrics Society Beers Criteria                   for Potentially Inappropriate Medication Use in Older Adults                                                                          8 



                                                                                                                                                                             Quality of          Strength of           2 

                                                                                                                                                                                                                       0 

       Organ System, Therapeutic Category, Drug(s)                                      Rationale                                         Recommendation                     Evidence         Recommendation           1 

                                                                                                                                                                                                                       9 

                                                                                                                                                                                                                       A 

                        b                                                                                                                                                                                              G 

      Anticholinergics                                                                                                                                                                                                 S 

                                                                                                                                                                                                                       B 

         First-generation antihistamines                     Highly anticholinergic; clearance reduced with advanced         Avoid                                          Moderate               Strong              E 

                                                                                                                                                                                                                       E 

            Brompheniramine                                  age, and tolerance develops when used as hypnotic; risk                                                                                                   R 

                                                                                                                                                                                                                       S 

            Carbinoxamine                                    of confusion, dry mouth, constipation, and other                                                                                                          C 

                                                                                                                                                                                                                       R 

            Chlorpheniramine                                 anticholinergic effects or toxicity                                                                                                                       I 

                                                                                                                                                                                                                       T 

                                                                                                                                                                                                                       E 

                                                                                                                                                                                                                       R 

            Clemastine                                       Use of diphenhydramine in situations such as acute 

                                                                                                                                                                                                                       I 

            Cyproheptadine                                   treatment of severe allergic reaction may be appropriate.                                                                                                 A 

                                                                                                                                                                                                                        ® 

            Dexbrompheniramine                                                                                                                                                                                         U 

                                                                                                                                                                                                                       P 

            Dexchlorpheniramine                                                                                                                                                                                        D 

                                                                                                                                                                                                                       A 

            Dimenhydrinate                                                                                                                                                                                             T 

                                                                                                                                                                                                                       E 

            Diphenhydramine (oral)                                                                                                                                                                                     E 

                                                                                                                                                                                                                       X 

            Doxylamine                                                                                                                                                                                                 P 

                                                                                                                                                                                                                       E 

            Hydroxyzine                                                                                                                                                                                                R 

                                                                                                                                                                                                                       T 

            Meclizine                                                                                                                                                                                                  P 

                                                                                                                                                                                                                       A 

            Promethazine                                                                                                                                                                                               N 

                                                                                                                                                                                                                       E 

            Pyrilamine                                                                                                                                                                                                 L 



           Triprolidine 

         Antiparkinsonian agents                             Not recommended for prevention or treatment of                  Avoid                                          Moderate               Strong 

            Benztropine (oral)                               extrapyramidal symptoms with antipsychotics; more 

           Trihexyphenidyl                                   effective agents available for treatment of Parkinson 

                                                             disease 

         Antispasmodics                                      Highly anticholinergic, uncertain effectiveness                 Avoid                                           Moderate              Strong 

           Atropine (excludes ophthalmic) 

            Belladonna alkaloids 

            Clidinium-chlordiazepoxide 

            Dicyclomine Homatropine 

              (excludes opthalmic) 

            Hyoscyamine 

            Methscopolamine 

            Propantheline 

            Scopolamine 

      Antithrombotics 

                                                                                                                                                                                                                       A 

         Dipyridamole, oral short acting (does               May cause orthostatic hypotension; more effective               Avoid                                          Moderate               Strong 

                                                                                                                                                                                                                       P 

         not apply to the extended-release                   alternatives available; IV form acceptable for use in                                                                                                     R 

                                                                                                                                                                                                                       I 

         combination with aspirin)                           cardiac stress testing                                                                                                                                    L 

                                                                                                                                                                                                                       2 

                                                                                                                                                                                                                       0 

                                                                                                                                                                                                                       1 

      Anti-infective 

                                                                                                                                                                                                                       9 

         Nitrofurantoin                                      Potential for pulmonary toxicity, hepatoxicity, and             Avoid in individuals with creatinine               Low                Strong              – 

                                                                                                                                                                                                                       V 

                                                             peripheral neuropathy, especially with long-term use;           clearance <30 mL/min or for long-term                                                     O 

                                                                                                                                                                                                                       L 

                                                             safer alternatives available                                    suppression                                                                               . 

                                                                                                                                                                                                                       6 

                                                                                                                                                                                                                       7 

       Cardiovascular                                                                                                                                                                                                 , 

                                                                                                                                                                                                                       N 

         Peripheral alpha-1 blockers for treatment           High risk of orthostatic hypotension and associated             Avoid use as an antihypertensive               Moderate               Strong              O 

                                                                                                                                                                                                                       . 

         of hypertension                                     harms, especially in older adults; not recommended as                                                                                                     4 



            Doxazosin                                        routine treatment for hypertension; alternative agents 

            Prazosin                                         have superior risk/beneﬁt proﬁle 

                                                                                                                                                                                                                      J 

                                                                                                                                                                                                                       A 

                                                                                                                                                                                                                       G 

           Terazosin 

         Central alpha-agonists                                                                                              Avoid as ﬁrst-line antihypertensive                Low                Strong              S 



esneciL snommoC evitaerC elbacilppa eht yb denrevog era selcitra AO ;esu fo selur rof yrarbiL enilnO yeliW no )snoitidnoc-dna-smret/moc.yeliw.yrarbilenilno//:sptth( snoitidnoC dna smreT eht eeS .]3202/80/32[ no yrarbiL enilnO yeliW ,htoonyaM dnalerI fO ytisrevinU lanoitaN yb 76751.sgj/1111.01/iod/moc.yeliw.yrarbilenilno.slanruojsga//:sptth morf dedaolnwoD ,4 ,9102 ,51452351  


----------------------- Page 2-----------------------

                                                                                                                                                                                                                                 J 

                                                                                                                                                                                                                                  A 

       Table 2  (Contd.)                                                                                                                                                                                                          G 

                                                                                                                                                                                                                                  S 



                                                                                                                                                                                      Quality of           Strength of 

       Organ System, Therapeutic Category, Drug(s)                                          Rationale                                            Recommendation                       Evidence          Recommendation            A 

                                                                                                                                                                                                                                  P 

                                                                                                                                                                                                                                  R 

                                                                                                                                                                                                                                  I 

          Clonidine for ﬁrst-line treatment                     High risk of adverse CNS effects; may cause bradycardia             Avoid other CNS alpha-agonists as                   Low                  Strong               L 

                                                                                                                                                                                                                                  2 

                                                                and orthostatic hypotension; not recommended as routine                                                                                                           0 

         of hypertension                                                                                                            listed                                                                                        1 

                                                                                                                                                                                                                                  9 

                                                                treatment for hypertension                                                                                                                                        – 

                                                                                                                                                                                                                                  V 

         Other CNS alpha-agonists 

            Guanabenz                                                                                                                                                                                                             O 

                                                                                                                                                                                                                                  L 

                                                                                                                                                                                                                                  . 

                                                                                                                                                                                                                                  6 

            Guanfacine 

                                                                                                                                                                                                                                  7 

            Methyldopa                                                                                                                                                                                                           , 

                                                                                                                                                                                                                                  N 

            Reserpine (>0.1 mg/day)                                                                                                                                                                                               O 

                                                                                                                                                                                                                                  . 

          Disopyramide                                          May induce heart failure in older adults because of potent          Avoid                                               Low                  Strong               4 



                                                                negative inotropic action; strongly anticholinergic; other 

                                                                antiarrhythmic drugs preferred 

          Dronedarone                                           Worse outcomes have been reported in patients taking                Avoid in individuals with permanent                 High                 Strong 

                                                                dronedarone who have permanent atrial ﬁbrillation or                atrial ﬁbrillation or severe or recently 

                                                                severe or recently decompensated heart failure.                     decompensated heart failure 

          Digoxin for ﬁrst-line treatment of atrial             Use in atrial ﬁbrillation: should not be used as a ﬁrst-line        Avoid this rate control agent as ﬁrst-       Atrial ﬁbrillation:    Atrial ﬁbrillation: 

         ﬁbrillation or of heart failure                        agent in atrial ﬁbrillation, because there are safer and            line therapy for atrial ﬁbrillation                  low                 strong 

                                                                more effective alternatives for rate control supported by 

                                                                                                                                    Avoid as ﬁrst-line therapy for heart           Heart failure:        Heart failure: 

                                                                high-quality evidence. 

                                                                                                                                    failure                                              low                 strong 

                                                                Use in heart failure: evidence for beneﬁts and harms of 

                                                                digoxin is conﬂicting and of lower quality; most but not all        If used for atrial ﬁbrillation or heart           Dosage                Dosage 

                                                                of the evidence concerns use in HFrEF. There is strong              failure, avoid dosages >0.125 mg/day          >0.125 mg/day:        >0.125 mg/day: 

                                                                evidence for other agents as ﬁrst-line therapy to reduce                                                             moderate                strong 

                                                                hospitalizations and mortality in adults with HFrEF. In 

                                                                heart failure, higher dosages are not associated with 

                                                                additional beneﬁt and may increase risk of toxicity. 

                                                                Decreased renal clearance of digoxin may lead to                                                                                                                  2 

                                                                                                                                                                                                                                  0 

                                                                increased risk of toxic effects; further dose reduction may                                                                                                       1 

                                                                                                                                                                                                                                  9 

                                                                be necessary in those with stage 4 or 5 chronic kidney                                                                                                            A 

                                                                                                                                                                                                                                  G 

                                                                disease.                                                                                                                                                          S 

                                                                                                                                                                                                                                  B 

          Nifedipine, immediate release                         Potential for hypotension; risk of precipitating myocardial         Avoid                                               High                 Strong               E 

                                                                                                                                                                                                                                  E 

                                                                                                                                                                                                                                  R 

                                                                                                                                                                                                                                  S 

                                                                ischemia 

         Amiodarone                                             Effective for maintaining sinus rhythm but has greater              Avoid as ﬁrst-line therapy for atrial               High                 Strong               C 

                                                                                                                                                                                                                                  R 

                                                                                                                                                                                                                                  I 

                                                                toxicities than other antiarrhythmics used in atrial                ﬁbrillation unless patient has heart                                                          T 

                                                                                                                                                                                                                                  E 

                                                                ﬁbrillation; may be reasonable ﬁrst-line therapy in patients        failure or substantial left ventricular                                                       R 

                                                                                                                                                                                                                                  I 

                                                                                                                                                                                                                                  A 

                                                                with concomitant heart failure or substantial left                  hypertrophy                                                                                    ® 

                                                                                                                                                                                                                                  U 

                                                                ventricular hypertrophy if rhythm control is preferred over                                                                                                       P 

                                                                                                                                                                                                                                  D 

                                                                                                                                                                                                                                  A 

                                                                rate control 

                                                                                                                                                                                                                                  T 

       Central nervous system                                                                                                                                                                                                     E 

                                                                                                                                                                                                                                  E 

                                                                                                                                                                                                                                  X 

         Antidepressants, alone or in combination               Highly anticholinergic, sedating, and cause orthostatic             Avoid                                               High                 Strong 

                                                                                                                                                                                                                                  P 

            Amitriptyline                                       hypotension; safety proﬁle of low-dose doxepin                                                                                                                    E 

                                                                                                                                                                                                                                  R 

            Amoxapine                                           (≤6 mg/day) comparable to that of placebo                                                                                                                         T 

                                                                                                                                                                                                                                  P 

            Clomipramine                                                                                                                                                                                                          A 

                                                                                                                                                                                                                                  N 

            Desipramine                                                                                                                                                                                                           E 

            Doxepin >6 mg/day                                                                                                                                                                                                     L 



            Imipramine 

                                                                                                                                                                                                                                  6 

                                                                                                                                                                                                           (Continued)            7 

                                                                                                                                                                                                                                  9 



esneciL snommoC evitaerC elbacilppa eht yb denrevog era selcitra AO ;esu fo selur rof yrarbiL enilnO yeliW no )snoitidnoc-dna-smret/moc.yeliw.yrarbilenilno//:sptth( snoitidnoC dna smreT eht eeS .]3202/80/32[ no yrarbiL enilnO yeliW ,htoonyaM dnalerI fO ytisrevinU lanoitaN yb 76751.sgj/1111.01/iod/moc.yeliw.yrarbilenilno.slanruojsga//:sptth morf dedaolnwoD ,4 ,9102 ,51452351  


----------------------- Page 3-----------------------

                                                                                                                                                                                                                       6 

                                                                                                                                                                                                                       8 

      Table 2  (Contd.)                                                                                                                                                                                                0 



                                                                                                                                                                             Quality of          Strength of 

                                                                                                                                                                                                                       2 

                                                                                                                                                                                                                       0 

       Organ System, Therapeutic Category, Drug(s)                                      Rationale                                         Recommendation                     Evidence         Recommendation           1 

                                                                                                                                                                                                                       9 

                                                                                                                                                                                                                       A 

            Nortriptyline                                                                                                                                                                                              G 

                                                                                                                                                                                                                       S 

            Paroxetine                                                                                                                                                                                                 B 

                                                                                                                                                                                                                       E 

                                                                                                                                                                                                                       E 

            Protriptyline                                                                                                                                                                                              R 

                                                                                                                                                                                                                       S 

                                                                                                                                                                                                                       C 

           Trimipramine 

                                                                                                                                                                                                                       R 

         Antipsychotics, ﬁrst (conventional) and             Increased risk of cerebrovascular accident (stroke) and         Avoid, except in schizophrenia or               Moderate              Strong              I 

                                                                                                                                                                                                                       T 

         second (atypical) generation                        greater rate of cognitive decline and mortality in persons      bipolar disorder, or for short-term use                                                   E 

                                                                                                                                                                                                                       R 

                                                                                                                                                                                                                       I 

                                                             with dementia                                                   as antiemetic during chemotherapy                                                         A 

                                                                                                                                                                                                                        ® 

                                                             Avoid antipsychotics for behavioral problems of dementia or                                                                                               U 

                                                                                                                                                                                                                       P 

                                                             delirium unless nonpharmacological options (eg, behavioral                                                                                                D 

                                                                                                                                                                                                                       A 

                                                             interventions) have failed or are not possible and the older                                                                                              T 

                                                                                                                                                                                                                       E 

                                                             adult is threatening substantial harm to self or others                                                                                                   E 

                                                                                                                                                                                                                       X 

         Barbiturates                                        High rate of physical dependence, tolerance to sleep            Avoid                                             High                Strong              P 

                                                                                                                                                                                                                       E 

           Amobarbital                                       beneﬁts, greater risk of overdose at low dosages                                                                                                          R 

                                                                                                                                                                                                                       T 

                                                                                                                                                                                                                       P 

            Butabarbital 

                                                                                                                                                                                                                       A 

                                                                                                                                                                                                                       N 

            Butalbital 

                                                                                                                                                                                                                       E 

            Mephobarbital                                                                                                                                                                                              L 

            Pentobarbital 

            Phenobarbital 

            Secobarbital 

         Benzodiazepines                                     Older adults have increased sensitivity to                      Avoid                                          Moderate               Strong 

         Short and intermediate acting:                      benzodiazepines and decreased metabolism of long- 

           Alprazolam                                        acting agents; in general, all benzodiazepines increase 

            Estazolam                                        risk of cognitive impairment, delirium, falls, fractures, and 

            Lorazepam                                        motor vehicle crashes in older adults 

            Oxazepam                                         May be appropriate for seizure disorders, rapid eye 

           Temazepam                                         movement sleep behavior disorder, benzodiazepine 

           Triazolam                                         withdrawal, ethanol withdrawal, severe generalized 

         Long acting:                                        anxiety disorder, and periprocedural anesthesia 

            Chlordiazepoxide (alone or in combination 

           with amitriptyline or clidinium) 

            Clonazepam 

            Clorazepate 

            Diazepam 

                                                                                                                                                                                                                       A 

                                                                                                                                                                                                                       P 

                                                                                                                                                                                                                       R 

            Flurazepam 

                                                                                                                                                                                                                       I 

            Quazepam                                                                                                                                                                                                   L 

                                                                                                                                                                                                                       2 

         Meprobamate                                         High rate of physical dependence; sedating                      Avoid                                           Moderate              Strong              0 

                                                                                                                                                                                                                       1 

                                                                                                                                                                                                                       9 

         Nonbenzodiazepine, benzodiazepine                   Nonbenzodiazepine benzodiazepine receptor agonist               Avoid                                          Moderate               Strong              – 

                                                                                                                                                                                                                       V 

         receptor agonist hypnotics (ie, “Z-drugs”)          hypnotics (ie, Z drugs) have adverse events similar to                                                                                                    O 

                                                                                                                                                                                                                       L 

            Eszopiclone                                      those of benzodiazepines in older adults (eg, delirium,                                                                                                   . 

                                                                                                                                                                                                                       6 

                                                                                                                                                                                                                       7 

           Zaleplon                                          falls, fractures); increased emergency room visits/                                                                                                      , 

                                                                                                                                                                                                                       N 

                                                                                                                                                                                                                       O 

           Zolpidem                                          hospitalizations; motor vehicle crashes; minimal 

                                                                                                                                                                                                                       . 

                                                             improvement in sleep latency and duration                                                                                                                 4 

         Ergoloid mesylates                                  Lack of efﬁcacy                                                 Avoid                                             High                Strong 

         (dehydrogenated ergot alkaloids) 

                                                                                                                                                                                                                      J 

         Isoxsuprine                                                                                                                                                                                                   A 

                                                                                                                                                                                                                       G 

       Endocrine                                                                                                                                                                                                       S 



esneciL snommoC evitaerC elbacilppa eht yb denrevog era selcitra AO ;esu fo selur rof yrarbiL enilnO yeliW no )snoitidnoc-dna-smret/moc.yeliw.yrarbilenilno//:sptth( snoitidnoC dna smreT eht eeS .]3202/80/32[ no yrarbiL enilnO yeliW ,htoonyaM dnalerI fO ytisrevinU lanoitaN yb 76751.sgj/1111.01/iod/moc.yeliw.yrarbilenilno.slanruojsga//:sptth morf dedaolnwoD ,4 ,9102 ,51452351  


----------------------- Page 4-----------------------

                                                                                                                                                                                                                                               J 

                                                                                                                                                                                                                                               A 

       Table 2  (Contd.)                                                                                                                                                                                                                       G 

                                                                                                                                                                                                                                               S 



                                                                                                                                                                                                 Quality of            Strength of 

       Organ System, Therapeutic Category, Drug(s)                                                Rationale                                               Recommendation                         Evidence           Recommendation             A 

                                                                                                                                                                                                                                               P 

                                                                                                                                                                                                                                               R 

                                                                                                                                                                                                                                               I 

          Androgens                                                 Potential for cardiac problems; contraindicated in men                  Avoid unless indicated for conﬁrmed                 Moderate                  Weak                 L 

                                                                                                                                                                                                                                                2 

                                                                                                                                                                                                                                                0 

             Methyltestosterone                                     with prostate cancer                                                    hypogonadism with clinical symptoms                                                                 1 

                                                                                                                                                                                                                                                9 

                                                                                                                                                                                                                                                – 

                                                                                                                                                                                                                                               V 

             Testosterone 

          Desiccated thyroid                                        Concerns about cardiac effects; safer alternatives                      Avoid                                                  Low                   Strong                O 

                                                                                                                                                                                                                                               L 

                                                                                                                                                                                                                                               . 

                                                                                                                                                                                                                                                6 

                                                                    available 

                                                                                                                                                                                                                                                7 

          Estrogens with or without progestins                      Evidence of carcinogenic potential (breast and                          Avoid systemic estrogen (eg, oral and            Oral and patch:        Oral and patch:            , 

                                                                                                                                                                                                                                               N 

                                                                    endometrium); lack of cardioprotective effect and                       topical patch)                                         high                  strong                O 

                                                                                                                                                                                                                                               . 

                                                                    cognitive protection in older women                                                                                                                                         4 

                                                                                                                                                                                             Vaginal cream          Topical vaginal 

                                                                    Evidence indicates that vaginal estrogens for the treatment             Vaginal cream or vaginal tablets: 

                                                                                                                                                                                                or vaginal         cream or tablets: 

                                                                    of vaginal dryness are safe and effective; women with a                 acceptable to use low-dose 

                                                                                                                                                                                                 tablets:                 weak 

                                                                    history of breast cancer who do not respond to                          intravaginal estrogen for management 

                                                                                                                                                                                                moderate 

                                                                    nonhormonal therapies are advised to discuss the risks and              of dyspareunia, recurrent lower 

                                                                    beneﬁts of low-dose vaginal estrogen (dosages of estradiol              urinary tract infections, and other 

                                                                    <25 μg twice weekly) with their healthcare provider                     vaginal symptoms 

          Growth hormone                                            Impact on body composition is small and associated with                 Avoid, except for patients rigorously                  High                  Strong 

                                                                    edema, arthralgia, carpal tunnel syndrome,                              diagnosed by evidence-based criteria 

                                                                    gynecomastia, impaired fasting glucose                                  with growth hormone deﬁciency due to 

                                                                                                                                            an established etiology 

          Insulin, sliding scale (insulin regimens                  Higher risk of hypoglycemia without improvement in                      Avoid                                               Moderate                 Strong 

          containing only short- or rapid-acting insulin            hyperglycemia management regardless of care setting. 

          dosed according to current blood glucose                  Avoid insulin regimens that include only short- or rapid- 

          levels without concurrent use of basal or                 acting insulin dosed according to current blood glucose 

          long-acting insulin)                                      levels without concurrent use of basal or long-acting 

                                                                    insulin. This recommendation does not apply to regimens 

                                                                    that contain basal insulin or long-acting insulin.                                                                                                                          2 

                                                                                                                                                                                                                                                0 

          Megestrol                                                 Minimal effect on weight; increases risk of thrombotic                  Avoid                                               Moderate                 Strong                 1 

                                                                                                                                                                                                                                                9 

                                                                    events and possibly death in older adults                                                                                                                                  A 

                                                                                                                                                                                                                                               G 

          Sulfonylureas, long acting                                Chlorpropamide: prolonged half-life in older adults; can                Avoid                                                  High                  Strong                S 

                                                                                                                                                                                                                                               B 

             Chlorpropamide                                         cause prolonged hypoglycemia; causes SIADH                                                                                                                                 E 

                                                                                                                                                                                                                                               E 

                                                                                                                                                                                                                                               R 

             Glimepiride                                            Glimepiride and glyburide: higher risk of severe                                                                                                                           S 

             Glyburide (also known as glibenclamide)                prolonged hypoglycemia in older adults                                                                                                                                     C 

                                                                                                                                                                                                                                               R 

                                                                                                                                                                                                                                               I 

       Gastrointestinal                                                                                                                                                                                                                        T 

                                                                                                                                                                                                                                               E 

          Metoclopramide                                            Can cause extrapyramidal effects, including tardive                     Avoid, unless for gastroparesis with                Moderate                 Strong                R 

                                                                                                                                                                                                                                               I 

                                                                                                                                                                                                                                               A 

                                                                    dyskinesia; risk may be greater in frail older adults and               duration of use not to exceed 12 weeks                                                              ® 

                                                                                                                                                                                                                                               U 

                                                                    with prolonged exposure                                                 except in rare cases                                                                               P 

                                                                                                                                                                                                                                               D 

          Mineral oil, given orally                                 Potential for aspiration and adverse effects; safer                     Avoid                                               Moderate                 Strong                A 

                                                                                                                                                                                                                                               T 

                                                                                                                                                                                                                                               E 

                                                                    alternatives available 

                                                                                                                                                                                                                                               E 

                                                                                                                                                                                                                                               X 

          Proton-pump inhibitors                                    Risk of Clostridium difﬁcile infection and bone loss and                Avoid scheduled use for >8 weeks                       High                  Strong 

                                                                                                                                                                                                                                               P 

                                                                    fractures                                                               unless for high-risk patients (eg, oral                                                            E 

                                                                                                                                                                                                                                               R 

                                                                                                                                            corticosteroids or chronic NSAID use),                                                             T 

                                                                                                                                                                                                                                               P 

                                                                                                                                            erosive esophagitis, Barrett esophagitis,                                                          A 

                                                                                                                                                                                                                                               N 

                                                                                                                                            pathological hypersecretory condition, or                                                          E 

                                                                                                                                            demonstrated need for maintenance                                                                  L 



                                                                                                                                            treatment (eg, because of failure of drug 

                                                                                                                                            discontinuation trial or H2-receptor                                                                6 

                                                                                                                                                                                                                                                8 

                                                                                                                                            antagonists)                                                                                        1 



                                                                                                                                                                                                                        (Continued) 



esneciL snommoC evitaerC elbacilppa eht yb denrevog era selcitra AO ;esu fo selur rof yrarbiL enilnO yeliW no )snoitidnoc-dna-smret/moc.yeliw.yrarbilenilno//:sptth( snoitidnoC dna smreT eht eeS .]3202/80/32[ no yrarbiL enilnO yeliW ,htoonyaM dnalerI fO ytisrevinU lanoitaN yb 76751.sgj/1111.01/iod/moc.yeliw.yrarbilenilno.slanruojsga//:sptth morf dedaolnwoD ,4 ,9102 ,51452351  


----------------------- Page 5-----------------------

                                                                                                                                                                                                                                   6 

                                                                                                                                                                                                                                   8 

       Table 2  (Contd.)                                                                                                                                                                                                           2 



                                                                                                                                                                                       Quality of           Strength of 

                                                                                                                                                                                                                                   2 

                                                                                                                                                                                                                                   0 

       Organ System, Therapeutic Category, Drug(s)                                           Rationale                                            Recommendation                       Evidence          Recommendation            1 

                                                                                                                                                                                                                                   9 

                                                                                                                                                                                                                                   A 

       Pain medications                                                                                                                                                                                                            G 

                                                                                                                                                                                                                                   S 

          Meperidine                                            Oral analgesic not effective in dosages commonly used;              Avoid                                             Moderate               Strong                B 

                                                                                                                                                                                                                                   E 

                                                                                                                                                                                                                                   E 

                                                                may have higher risk of neurotoxicity, including delirium,                                                                                                         R 

                                                                                                                                                                                                                                   S 

                                                                                                                                                                                                                                   C 

                                                                than other opioids; safer alternatives available 

                                                                                                                                                                                                                                   R 

          Non–cyclooxygenase-selective NSAIDs, oral:            Increased risk of gastrointestinal bleeding or peptic ulcer         Avoid chronic use, unless other                   Moderate                Strong               I 

                                                                                                                                                                                                                                   T 

            Aspirin >325 mg/day                                 disease in high-risk groups, including those >75 years or           alternatives are not effective and                                                             E 

                                                                                                                                                                                                                                   R 

                                                                                                                                                                                                                                   I 

            Diclofenac                                          taking oral or parenteral corticosteroids, anticoagulants,          patient can take gastroprotective                                                              A 

                                                                                                                                                                                                                                    ® 

            Diﬂunisal                                           or antiplatelet agents; use of proton-pump inhibitor or             agent (proton-pump inhibitor or                                                                U 

                                                                                                                                                                                                                                   P 

            Etodolac                                            misoprostol reduces but does not eliminate risk. Upper              misoprostol)                                                                                   D 

                                                                                                                                                                                                                                   A 

            Fenoprofen                                          gastrointestinal ulcers, gross bleeding, or perforation                                                                                                            T 

                                                                                                                                                                                                                                   E 

            Ibuprofen                                           caused by NSAIDs occur in ~1% of patients treated for                                                                                                              E 

                                                                                                                                                                                                                                   X 

            Ketoprofen                                          3-6 months and in ~2%-4% of patients treated for 1 year;                                                                                                           P 

                                                                                                                                                                                                                                   E 

            Meclofenamate                                       these trends continue with longer duration of use. Also                                                                                                            R 

                                                                                                                                                                                                                                   T 

            Mefenamic acid                                      can increase blood pressure and induce kidney injury.                                                                                                              P 

                                                                                                                                                                                                                                   A 

                                                                                                                                                                                                                                   N 

            Meloxicam                                           Risks are dose related. 

                                                                                                                                                                                                                                   E 

            Nabumetone                                                                                                                                                                                                             L 

            Naproxen 

            Oxaprozin 

            Piroxicam 

            Sulindac 

            Tolmetin 

          Indomethacin                                          Increased  risk  of  gastrointestinal  bleeding/peptic  ulcer       Avoid                                             Moderate               Strong 

          Ketorolac, includes parenteral                        disease  and  acute  kidney  injury  in  older  adults 

                                                                Indomethacin is more likely than other NSAIDs to have 

                                                                adverse CNS effects. Of all the NSAIDs, indomethacin 

                                                                has the most adverse effects. 

          Skeletal muscle relaxants                             Most muscle relaxants poorly tolerated by older adults              Avoid                                             Moderate               Strong 

            Carisoprodol                                        because some have anticholinergic adverse effects, 

            Chlorzoxazone                                       sedation, increased risk of fractures; effectiveness at 

            Cyclobenzaprine                                     dosages tolerated by older adults questionable 

            Metaxalone 

            Methocarbamol 

            Orphenadrine 

                                                                                                                                                                                                                                   A 

                                                                                                                                                                                                                                   P 

                                                                                                                                                                                                                                   R 

       Genitourinary 

                                                                                                                                                                                                                                   I 

          Desmopressin                                          High risk of hyponatremia; safer alternative treatments             Avoid for treatment of nocturia or                Moderate                Strong               L 

                                                                                                                                                                                                                                   2 

                                                                                                                                    nocturnal polyuria                                                                             0 

                                                                                                                                                                                                                                   1 

                                                                                                                                                                                                                                   9 

                                                                                                                                                                                                                                   – 

                                                                                                                                                                                                                                   V 

       Abbreviations: CNS, central nervous system; HFrEF, heart failure with reduced ejection fraction; NSAID, nonsteroidal anti-inﬂammatory drug; SIADH, syndrome of inappropriate antidiuretic hormone secretion.                O 

       a                                                                                                                                                                                                                           L 

        The primary target audience  is the practicing clinician. The intentions of the criteria include (1) improving the selection of prescription drugs by  clinicians and patients; (2) evaluating patterns of drug use within . 

                                                                                                                                                                                                                                   6 

                                                                                                                                                                                                                                   7 

        populations; (3) educating clinicians and patients on proper drug usage; and (4) evaluating health-outcome, quality-of-care, cost, and utilization data.                                                                  , 

       b                                                                                                                                                                                                                           N 

                                                                                                                                                                                                                                   O 

        See also criterion on highly anticholinergic antidepressants. 

                                                                                                                                                                                                                                   . 

                                                                                                                                                                                                                                   4 



                                                                                                                                                                                                                                  J 

                                                                                                                                                                                                                                   A 

                                                                                                                                                                                                                                   G 

                                                                                                                                                                                                                                   S 



esneciL snommoC evitaerC elbacilppa eht yb denrevog era selcitra AO ;esu fo selur rof yrarbiL enilnO yeliW no )snoitidnoc-dna-smret/moc.yeliw.yrarbilenilno//:sptth( snoitidnoC dna smreT eht eeS .]3202/80/32[ no yrarbiL enilnO yeliW ,htoonyaM dnalerI fO ytisrevinU lanoitaN yb 76751.sgj/1111.01/iod/moc.yeliw.yrarbilenilno.slanruojsga//:sptth morf dedaolnwoD ,4 ,9102 ,51452351  

